Errol de Souza
Chairman bei CYCLERION THERAPEUTICS, INC.
Vermögen: 33 Mio $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Kevin Gorman | M | 66 | 32 Jahre | |
Srinivas Rao | M | 55 |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | 5 Jahre |
Rory Riggs | M | 71 | 28 Jahre | |
Brian McKeon | M | 61 | 21 Jahre | |
Arnon Rosenthal | M | 68 | 11 Jahre | |
Terry McGuire | M | 68 | 11 Jahre | |
Gary Lyons | M | 73 | 31 Jahre | |
Peter Hecht | M | 60 | 5 Jahre | |
Andrés-Pablo Montefeltro | M | - |
nLife Therapeutics SL
nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | 15 Jahre |
Spyridon Papapetropoulos | M | 52 | 1 Jahre | |
Alan Fisher | M | 71 | 8 Jahre | |
Pablo Legorreta | M | 60 | 28 Jahre | |
Louis Lavigne | M | 75 | 6 Jahre | |
Danielle Pasqualone | M | - | 5 Jahre | |
Adrian Hinton | M | 72 | 5 Jahre | |
Catherine Engelbert | F | 59 | 4 Jahre | |
Mario Giuliani | M | 52 | 4 Jahre | |
George Lloyd | M | 64 | 13 Jahre | |
Saraswati Kenkare-Mitra | M | 57 | 3 Jahre | |
Bonnie Bassler | M | 61 | 4 Jahre | |
Andrew Carry Kruegel | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
John Hart | M | - | 16 Jahre | |
Kristine Yaffe | M | 61 | 5 Jahre | |
Paula Hammond | M | 60 | 4 Jahre | |
Christopher Hite | M | 57 | 4 Jahre | |
Aaron Weaver | M | 43 | 4 Jahre | |
Elizabeth Garofalo | M | 66 | 3 Jahre | |
Kristin Stafford | F | 42 | 8 Jahre | |
Peter Davies | M | 43 | 3 Jahre | |
Sean Weisberg | M | - | 4 Jahre | |
Marc Grasso | M | 51 | 2 Jahre | |
Virginia DeJesus-Rueff | F | - | - | |
Jane Ryan | M | 65 | 4 Jahre | |
James Reddoch | M | 54 | 16 Jahre | |
George Grofik | M | - | 4 Jahre | |
Ted Love | M | 65 | 4 Jahre | |
Leslie Norwalk | F | 58 | 26 Jahre | |
Steven E. Hyman | M | 71 | 2 Jahre | |
David Wehner | M | 54 | 6 Jahre | |
Marshall Urist | M | 48 | 11 Jahre | |
David Wilson | M | 61 | 8 Jahre | |
Dimitri Grigoriadis | M | 65 | 31 Jahre | |
Richard Pops | M | 62 | 26 Jahre | |
Henry Fernandez | M | 65 | 4 Jahre | |
Gregory Norden | M | 66 | 4 Jahre | |
David Hodgson | M | 67 | 2 Jahre | |
Joseph Hull | M | 71 | 19 Jahre | |
Arthur McGivern | M | - | 2 Jahre | |
Bill Wilson | M | - | 28 Jahre | |
Richard Scheller | M | 70 | 6 Jahre | |
Laurence Reilly | M | 42 | - | |
Sarah Cata | F | - | 10 Jahre | |
Sara Klymkowsky | F | - | 12 Jahre | |
Mina Fukuda | F | - | 9 Jahre | |
Christine Grueniger | F | - | 4 Jahre | |
Jessica Veeramachaneni | F | - | 13 Jahre | |
Charles Wolfus | M | - | 5 Jahre | |
John F. Chin | M | 58 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 26 Jahre |
Dalibor Sames | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
Timothy Cunningham | M | 62 | 1 Jahre | |
Gary Romano | M | 63 | 2 Jahre | |
Clare Hunt | F | - | 7 Jahre | |
Tina Hunt | M | 56 | 18 Jahre | |
Kristina Cutter | F | - | 5 Jahre | |
Gabriel Alvarado | M | - |
nLife Therapeutics SL
nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | - |
Terrance Coyne | M | 42 | 14 Jahre | |
Brienne Kugler | F | - | 10 Jahre | |
Sandy Balkin | M | - | 3 Jahre | |
Dana Flanders | M | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
John P. Richard | M | 66 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 Jahre |
Solomon Steiner | M | 86 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 8 Jahre |
Julia Brown | F | 76 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | - |
Stephen Hill | M | 65 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 7 Jahre |
Joseph deBethizy | M | 74 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 15 Jahre |
Alan Musso | M | 62 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 Jahre |
John Kelley | M | 70 |
Hoechst Marion Roussel, Inc.
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 9 Jahre |
Joseph A. Mollica | M | 83 | 20 Jahre | |
Wylie W. Vale | M | 82 | - | |
Seline E. Miller | F | 55 | 2 Jahre | |
Stephen Birrell | M | - | 11 Jahre | |
Graeme Roy Kaufman | M | 74 | 4 Jahre | |
Andreas Busch | M | 59 |
Hoechst Marion Roussel, Inc.
| 6 Jahre |
John Duncan Higgons | M | 69 |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 3 Jahre |
C. Payne | M | 61 | 4 Jahre | |
Pierre Legault | M | 63 |
Hoechst Marion Roussel, Inc.
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 5 Jahre |
Augustine Lawlor | M | 67 | 8 Jahre | |
Gerard Michel | M | 60 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 7 Jahre |
Brian Pereira | M | 65 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 8 Jahre |
Alan Dunton | M | 70 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 10 Jahre |
G. Steven Burrill | M | 79 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 Jahre |
Mark B. Skaletsky | M | 75 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 Jahre |
Anjeza Gjino | F | 41 | 4 Jahre | |
Chuck Wilson | M | 59 |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 7 Jahre |
Margaret E. Valeur-Jensen | M | 67 | - | |
Lawrence Steinman | M | 76 | 8 Jahre | |
Trevor William Tappenden | M | - | 10 Jahre | |
Robert G. Schaub | M | - |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | - |
Andrea Hunt | F | 64 | 6 Jahre | |
Kevin B. Churchwell | M | 62 | 2 Jahre | |
Andrew Hetherington | M | - | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 87 | 87,00% |
Australien | 13 | 13,00% |
Spanien | 2 | 2,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Errol de Souza
- Persönliches Netzwerk